{
    "clinical_study": {
        "@rank": "127617", 
        "arm_group": {
            "arm_group_label": "BAY2010112", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is the first study where BAY2010112 is given to humans. Patients with castration\n      resistant prostate cancer will be treated. Every patient will receive drug treatment, there\n      is no placebo group. Patients will receive different dosages of BAY2010112 to determine the\n      safety, tolerability and maximum tolerated dose (MTD) of BAY2010112.\n\n      The study will also assess the pharmacokinetics and the clinical efficacy of BAY2010112.\n\n      BAY2010112 will be given daily as subcutaneous injection. Treatment will be stopped if the\n      tumor continues to grow, if side effects, which the patient cannot tolerate, occur or if the\n      patient decides to exit treatment."
        }, 
        "brief_title": "First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostatic Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Prostatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male subjects, aged >/= 18 years\n\n          -  Subjects with histologically or cytologically proven advanced castration-resistant\n             prostate cancer (CRPC)\n\n               -  who failed at least 1 taxane regimen and are refractory to abiraterone and/or\n                  enzalutamide therapy OR\n\n               -  who have actively refused any treatment which would be regarded standard.\n\n          -  Subjects should have undergone bilateral orchiectomy or should be on continuous\n             androgen deprivation therapy with a gonadotropin releasing hormone agonist or\n             antagonist.\n\n          -  Subjects must have shown progressive disease after discontinuation of anti-androgen\n             therapy (i.e. flutamide, bicalutamide or nilutamide) before study drug treatment.\n\n          -  Total serum testosterone should be less than 50 ng/ml or 1.7 nmol/L\n\n          -  Evidence of progressive disease, defined as one or more (Prostate Cancer Working\n             Group 2 (PCWG2) criteria):\n\n          -  PSA level of at least 2 ng/ml that has risen on at least 2 successive occasions at\n             least 1 week apart\n\n          -  Nodal (in lymph nodes >/= 2cm) or visceral progression as defined by Response\n             Evaluation Criteria in Solid Tumors (RECIST)\n\n          -  Appearance of one more new lesions in bone scan\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2\n\n          -  Life expectancy of at least 3 months\n\n        Exclusion Criteria:\n\n          -  Any anticancer therapy or immunotherapy within 4 weeks of start of first dose\n\n          -  Confirmed history or current autoimmune disease or other diseases resulting in\n             permanent immunosuppression or requiring permanent immunosuppressive therapy\n\n          -  Prior radiotherapy (local palliative radiotherapy is permitted)\n\n          -  History of allergic reactions to monoclonal antibody therapy\n\n          -  History of clinical significant cardiac disease: including unstable angina, acute\n             myocardial infarction within 6 months prior to first study treatment, congestive\n             heart failure \u2265New York Heart Association (NYHA) Class III), and arrhythmia requiring\n             therapy except for betablockers, calcium channel blockers and digoxin or uncontrolled\n             hypertension, despite optimal medical management\n\n          -  Clinically relevant findings in the electrocardiogram (ECG) such as a second- or\n             third-degree AV block, prolongation of the QRS complex over 120 msec or of the QT\n             interval corrected for heart rate (QTc)-interval over 450 msec\n\n          -  Current evidence or history of uncured (i.a. any absolute risk of latent infection)\n             of hepatitis B or C or human immunodeficiency virus (HIV) infection\n\n          -  Chronic systemic corticosteroid therapy\n\n          -  Seizure disorder requiring therapy (such as steroids or anti-epileptics)\n\n          -  Subjects unable to inject the study drug subcutaneously"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01723475", 
            "org_study_id": "15590", 
            "secondary_id": "2012-000691-42"
        }, 
        "intervention": {
            "arm_group_label": "BAY2010112", 
            "description": "Subcutaneous (s.c.) administration once daily. Starting dose will be 0.5 \u00b5g ; dose will be escalated dependent on any dose limiting toxicities", 
            "intervention_name": "BAY2010112", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Phase I", 
            "Dose Escalation", 
            "Prostate cancer", 
            "Antibodies", 
            "Bispecific T-cell Engager (BiTE)"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria", 
                        "state": "Ober\u00f6sterreich", 
                        "zip": "4010"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "zip": "1100"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "zip": "1100"
                    }
                }, 
                "status": "Terminated"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "state": "Baden-W\u00fcrttemberg", 
                        "zip": "69120"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "W\u00fcrzburg", 
                        "country": "Germany", 
                        "state": "Bayern", 
                        "zip": "97080"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "12200"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Germany"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY2010112 Given Once Daily by Subcutaneous Administration in Subjects With Castration-resistant Prostate Cancer", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Agency for Health and Food Safety", 
                "Germany: Paul-Ehrlich-Institut"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years or longer if indicated"
            }, 
            {
                "description": "MTD is measured by adverse event profile at the end of Cycle 1. MTD will be the highest dose level achieved during dose escalation where the incidence of dose-limiting toxicities (DLTs) is below 20%", 
                "measure": "Maximum Tolerated Dose (MTD)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years or longer if indicated"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01723475"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "23623807", 
            "citation": "Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol. 2013 Jun;17(3):385-92. doi: 10.1016/j.cbpa.2013.03.029. Epub 2013 Apr 25. Review."
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum drug concentration (Cmax) of BAY2010112 in serum after single and multiple doses administration", 
                "safety_issue": "Yes", 
                "time_frame": "Cycle 1 Day1 and 15; (1 Cycle is 21 days long)"
            }, 
            {
                "measure": "Area under the concentration versus time curve (AUC) from zero to infinity after single (first) and multiple doses of BAY2010112", 
                "safety_issue": "Yes", 
                "time_frame": "Cycle 1 (1 Cycle is 21 days long)"
            }, 
            {
                "description": "Tumor response is measured by measurable lesions", 
                "measure": "Tumor response", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years or longer if indicated"
            }, 
            {
                "description": "PSA response is measured by maximum decline in PSA that occurs at any point after treatment", 
                "measure": "Prostate-specific antigen (PSA) response", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years or longer if indicated"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}